TransMedics Group, Inc. (TMDX): Results of Operations and Financial Condition
TransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and
How this was made
The 30-second read
Why it matters
The key tradable items are the Q2 revenue and earnings figures, the operating expense increase tied to OCS Kidney and Gen 3.0/clinical programs, and the raised low end of full-year revenue guidance (excluding PAD Aviation revenue and assuming no incremental ENHANCE Part B and DENOVO trial revenue).
Market read
This is a company-specific earnings and guidance update with explicit revenue growth and a guidance raise, but profitability declined due to higher planned investment and cost mix.
What to watch
Operating expenses jumped to $89.5M from $60.0M, and operating income fell to $23.7M; the market may re-rate the stock on margin trajectory rather than revenue growth alone.
TransMedics reported second-quarter total revenue of $189.9 million, up 21%, raised the low end of full-year 2026 revenue guidance, and reported lower operating income and net income.
Revenue grew 21%, with service revenue up 29% and full-year revenue guidance raised at the low end, but gross margin declined to 60%, operating income declined 35%, and diluted net income per share declined 55%.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $189.9 million | – | 21% |
| Net product revenueGAAP | $111.2 million | – | 16% |
| Service revenueGAAP | $78.8 million | – | 29% |
| Gross profitGAAP | $ 113,198 (in thousands) | – | – |
| Gross marginGAAP | 60 % | – | – |
| Research, development and clinical trials expenseGAAP | $ 31,632 (in thousands) | – | – |
| Selling, general and administrative expenseGAAP | $ 57,830 (in thousands) | – | – |
| Total operating expensesGAAP | $89.5 million | – | – |
| Stock compensation expenseGAAP | $8.2 million | – | – |
| Income from operationsGAAP | $23.7 million | – | -35 % |
| Operating marginGAAP | 12.5 % | – | -1074bps |
| Adjusted income from operationsnon-GAAP | $25.8 million | – | -29 % |
| Adjusted operating marginnon-GAAP | 13.6 % | – | -960bps |
| Net incomeGAAP | $14.7 million | – | – |
| Diluted net income per shareGAAP | $0.41 | – | -55 % |
| Basic net income per shareGAAP | $ 0.42 | – | – |
| Adjusted net incomenon-GAAP | $16.2 million | – | – |
| Adjusted diluted net income per sharenon-GAAP | $0.44 | – | -52 % |
| Six months ended June 30 total revenueGAAP | $ 363,881 (in thousands) | – | 21 % |
| Six months ended June 30 income from operationsGAAP | $ 37,033 (in thousands) | – | -42 % |
| Six months ended June 30 net incomeGAAP | $ 21,997 (in thousands) | – | – |
| Six months ended June 30 diluted net income per shareGAAP | $ 0.61 | – | -62 % |
| Six months ended June 30 adjusted diluted net income per sharenon-GAAP | $ 0.75 | – | -55 % |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Net product revenueThe company cited increased utilization of the Organ Care System, primarily in Liver and Heart through the National OCS Program. | $111.2 million | – | 16% |
| Service revenueThe company cited additional revenue generated by TransMedics logistics services. | $78.8 million | – | 29% |
full-year 2026 outlook
- Revenue$737 million to $757 million
- NoteGuidance excludes any revenue attributable to the recent strategic investment in PAD Aviation service GmbH.
- NoteGuidance assumes no incremental revenue from the ENHANCE Part B and DENOVO clinical trials.
- NoteGuidance represents approximately 22% to 25% growth compared to the company’s prior year revenue.
What drove it
- Total revenue growth was driven primarily by increased OCS utilization, primarily in Liver and Heart through the NOP, and additional logistics-services revenue.
- Service revenue grew 29%, faster than net product revenue growth of 16%.
- The company completed its strategic investment in PAD Aviation on July 1, 2026 as a first step toward a dedicated organ transplantation air logistics network across Europe and beyond.
- Operating-expense growth was driven primarily by planned investment in OCS Kidney, Gen 3.0 and clinical programs, together with selected infrastructure investments required to support growth.
Concerns
- Gross margin was 60%, compared with 61% in the prior-year period. The company attributed the decrease primarily to a higher mix of service revenue and temporary product-cost factors, including inventory provisioning and trial-related solution cost, partly offset by improved logistics efficiency.
- Income from operations was $23.7 million compared to $36.6 million, while operating margin was 12.5% compared to 23.2%.
- Net income was $14.7 million compared to $34.9 million, and diluted net income per share was $0.41 compared to $0.92.
- The company disclosed that it has identified a material weakness in its internal control over financial reporting.
What to watch
- Execution of the full-year 2026 revenue guidance range of $737 million to $757 million, which excludes PAD Aviation revenue.
- The pace of service-revenue growth and its effect on gross margin.
- Temporary product-cost factors, including inventory provisioning and trial-related solution cost, and the extent to which improved logistics efficiency offsets them.
- Spending on OCS Kidney, Gen 3.0, clinical programs and growth-supporting infrastructure.
- Revenue contributions, if any, from PAD Aviation, which are excluded from the full-year 2026 revenue guidance.
- Potential incremental revenue from the ENHANCE Part B and DENOVO clinical trials, which is not assumed in guidance.
Balance sheet and cash flow
- Cash was $472.7 million as of June 30, 2026.
- Cash: $ 472,675 (in thousands) as of June 30, 2026, compared with $ 488,366 (in thousands) as of December 31, 2025.
- Convertible senior notes, net: $ 454,260 (in thousands) as of June 30, 2026, compared with $ 452,804 (in thousands) as of December 31, 2025.
- Current portion of long-term debt: $ 20,000 (in thousands) as of June 30, 2026, compared with $ 10,000 (in thousands) as of December 31, 2025.
- Long-term debt, net: $ 39,743 (in thousands) as of June 30, 2026, compared with $ 49,587 (in thousands) as of December 31, 2025.
- Finance lease liability: $ 347,660 (in thousands) as of June 30, 2026.
- No operating cash flow or free cash flow was reported in the filing.
Analysis
TransMedics delivered $189.9 million of second-quarter revenue, a 21% increase from $157.4 million in the second quarter of 2025. Growth reflected increased OCS utilization, primarily in Liver and Heart through the NOP, and additional logistics-services revenue. Service revenue grew 29% to $78.8 million, exceeding the 16% increase in net product revenue to $111.2 million. For the first six months, total revenue was $363.9 million, up 21% from $300.9 million.
The revenue mix and cost factors pressured profitability. Gross margin was 60%, compared with 61% in the prior-year period, which the company attributed primarily to a higher mix of service revenue, inventory provisioning and trial-related solution cost. Total operating expenses increased to $89.5 million from $60.0 million, led by investments in OCS Kidney, Gen 3.0, clinical programs and growth-supporting infrastructure. As a result, GAAP operating income declined to $23.7 million from $36.6 million and operating margin declined to 12.5% from 23.2%.
GAAP net income was $14.7 million, or $0.41 per diluted share, compared with $34.9 million, or $0.92 per diluted share. Adjusted income from operations was $25.8 million, compared with $36.6 million, while adjusted operating margin was 13.6%, compared with 23.2%. Adjusted net income was $16.2 million, or $0.44 per diluted share, compared with $34.9 million, or $0.92 per diluted share. The second-quarter non-GAAP adjustments consisted of transaction-related costs, headquarters relocation costs and ERP implementation costs.
The company raised the low end of its full-year 2026 revenue guidance to $737 million to $757 million from the previously reported range of $727 million to $757 million. The updated guidance excludes revenue attributable to PAD Aviation, assumes no incremental revenue from the ENHANCE Part B and DENOVO clinical trials, and represents approximately 22% to 25% growth compared to prior-year revenue. TransMedics completed its PAD Aviation strategic investment on July 1, 2026, positioning it as an additional logistics-network initiative outside the stated guidance.
Cash was $472.7 million at June 30, 2026, compared with $488.4 million at December 31, 2025. The balance sheet also reported $454.3 million of convertible senior notes, net, $20.0 million of current long-term debt, $39.7 million of long-term debt, net, and $347.7 million of finance lease liability. The filing did not report operating cash flow, free cash flow, share repurchases or dividends. The central reported tradeoff is continued revenue and service growth alongside lower gross margin and materially lower operating and net income as the company funds product, clinical, infrastructure and logistics initiatives.
Management, verbatim
The second quarter was a defining one for TransMedics: record revenue, accelerating service growth, and sequential gross margin expansion, all as we invested aggressively in our strategic priorities.
Waleed Hassanein, MD, President and Chief Executive Officer
Let me be direct about how we see our business: we are building TransMedics to remain a growth company in the near, mid, and long terms. We are deploying capital behind four distinct growth opportunities that we believe will drive substantial revenue growth with a compelling operating profile at scale.
Waleed Hassanein, MD, President and Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons for revenue, product revenue, service revenue, gross margin, operating expenses, operating income, net income, and earnings per share were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Share repurchases were not reported.
- Dividends were not reported.
- Forward guidance for gross margin, operating expenses and tax rate was not reported.
- A separate previous-release outlook section was not provided; therefore, no reported actual-versus-prior-guidance comparison is included.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
TransMedics filed an 8-K with Exhibit 99.1 reporting second quarter 2026 results and updating full-year 2026 revenue guidance.
Ticker impact
TransMedics reported Q2 2026 revenue of $189.9M (+21% YoY) and raised full-year 2026 revenue guidance low end to $737M-$757M.
Near-term bias upward on guidance confidence, with potential volatility if investors focus on the operating margin and expense step-up.
The filing includes specific Q2 results, a raised revenue guidance range, and detailed drivers (OCS utilization, service growth, higher operating expenses for Kidney/Gen 3.0/clinical programs).
Market effects
Reinforces demand/utilization momentum in organ preservation and transplant logistics services, potentially supporting sentiment for medical technology peers tied to transplant workflows.
Limited direct regional read-through; PAD Aviation investment is Europe-focused but the guidance excludes PAD Aviation revenue.
Could modestly improve confidence in cross-border organ logistics buildout, though financial impact is not included in the raised guidance.
Counterpoint
Investors may discount the guidance raise if they believe service mix and temporary product-cost factors will pressure profitability further as planned investments ramp.
Key entities
- companyTransMedics Group, Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and raising full-year 2026 revenue guidance.
- private_companyPAD Aviation service GmbH
Germany-based private aviation operator in which TransMedics completed a strategic investment on July 1, 2026; PAD revenue is excluded from guidance.
